---
title: "10x Genomics and BioTuring Partner to Streamline Single Cell and Spatial Data Analysis"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273712381.md"
datetime: "2026-01-26T14:01:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273712381.md)
  - [en](https://longbridge.com/en/news/273712381.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273712381.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273712381.md) | [English](https://longbridge.com/en/news/273712381.md)


# 10x Genomics and BioTuring Partner to Streamline Single Cell and Spatial Data Analysis

10x Genomics Inc. has announced a strategic collaboration with BioTuring to streamline and accelerate single cell and spatial data analysis. The partnership integrates 10x Genomics’ Chromium, Xenium, and Visium platforms with BioTuring’s advanced analytical ecosystem, delivering a seamless end-to-end workflow for researchers working with complex single cell and spatial multiomics data. The collaboration aims to reduce fragmented analysis workflows and enhance the speed and depth of biological interpretation by leveraging BioTuring’s GPU-accelerated architecture and coordinated educational resources. Additionally, 10x Genomics customers new to BioTuring will receive a 30-day free access period to BioTuring’s analysis platform, with preferred pricing available thereafter. By mid-2026, the partnership is expected to enable direct data transfer from 10x Cloud Analysis into BioTuring’s platforms, further simplifying the analysis process. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [10X Genomics (TXG.US)](https://longbridge.com/zh-HK/quote/TXG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)

## 相關資訊與研究

- [10x Genomics and Cancer Research Institute Launch AI-Driven Immuno-Oncology Collaboration](https://longbridge.com/zh-HK/news/272282573.md)
- [GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG](https://longbridge.com/zh-HK/news/276216391.md)
- [10x Genomics und PharosAI gründen Konsortium zur KI-gestützten Krebsforschung](https://longbridge.com/zh-HK/news/274825887.md)
- [10x Genomics $TXG Holdings Decreased by Federated Hermes Inc.](https://longbridge.com/zh-HK/news/274516094.md)
- [Denali Therapeutics wins FDA accelerated approval for AVLAYAH to treat neurologic manifestations of Hunter syndrome](https://longbridge.com/zh-HK/news/280519141.md)